Is DNA sequencing the next big thing in finance? If you believe it is, then investing in Luke Lango’s G.C.T. (DNA Sequencing) Stock Pick could potentially provide an outsized return for your portfolio.
Luke Lango’s G.C.T. (DNA Sequencing) Stock Pick is a company that has been in the business of genomics for quite some time now. They have also been making great strides in the field of DNA sequencing, which is what they are focused on. Their stock price has gone up quite a bit as well, so it might be worth looking into this company for your own portfolio.
Luke Lango recently published a presentation on InvestorPlace on “G.C.T. technology,” which he says is part of a “$80 trillion DNA revolution.”
During the presentation, Lango mentioned a “little-known business” that is “dead center of this new digital revolution” and “may be the next Microsoft,” according to some.
What is GCT technology, and how does it work? And what is the stock that Lango is teasing?
DNA sequencing and synthetic biology are the technologies Lango is alluding to. In a paper titled “The Next Microsoft: The Software Firm Powering the $80 Trillion DNA Revolution,” he reveals the identity of the company he’s bullish on (and why).
However, I investigated his hints to determine which stock he was taunting. And I’ll show you what I found out about his “#1 GCT firm” in this post (including the ticker symbol).
I also discovered a second stock he mentioned during his presentation.
So I’ll tell you about it as well.
But first, let’s look at Luke Lango’s forecast based on G.C.T. technology (also known as DNA sequencing).
What Is G.C.T. Technology and How Does It Work? (Luke Lango’s DNA Sequencing Prediction Dismantled)
Luke Lango began his recent InvestorPlace presentation, called “The $80 Trillion Device,” by directing attendees to the “gadget” below.
Investorplace.com is the source for this information.
The technology within, which Luke Lango refers to as “G.C.T.,” is expected to “reinvent trillion-dollar businesses throughout the globe,” according to Luke Lango.
So, what exactly is G.C.T?
“Genetic Coding Technologies,” or G.C.T., seems to be a word coined by Luke Lango to describe DNA sequencing. And the device he demonstrated in his talk was a DNA sequencer (also known as a machine that sequences an organism’s DNA).
“However, I’m sure you’re wondering…” What is G.C.T. technology, and how does it work?
It all begins with the device I just showed you.
This little device can read your DNA and save, display, and analyze it on a computer, believe it or not.
A DNA Sequencer is what it’s called.
And it’s one of the most cutting-edge G.C.T. – or ‘Genetic Coding Technologies’ – applications.”
What is the definition of DNA sequencing? DNA sequencing, according to Genome.gov, is a laboratory method for identifying the precise sequence of bases (A, C, G, and T) in a DNA molecule.
A DNA sequencing machine, instead of employing computer code (1s and 0s), examines DNA code, which is made up of As, Cs, Gs, and Ts.
DNA sequencing has been around since the late 1970s. However, DNA sequencing devices have improved in quality, cost, and speed over time. And the technology’s potential applications go well beyond industries like healthcare.
DNA sequencing, for example, is a method utilized in synthetic biology, a multidisciplinary field of science that includes constructing or redesigning “things” based on nature.
In the years ahead, this technology has the potential to disrupt a wide range of sectors, including healthcare, agriculture, manufacturing, and energy.
While Lango’s presentation may come off as a little exaggerated or “salesy” (at least, that’s how I saw it), the trend he’s pursuing is noteworthy.
In the last several months, he’s the sixth well-known “investment expert” I’ve seen hawking the DNA sequencing / synthetic biology field.
As a result, this has recently been a “hot trend” among stock pickers.
In any case, Lango centered his presentation on how GCT technology may affect three major industries: healthcare, food, and manufacturing.
- “The End of Genetic Diseases” was the first major “GCT effect” he mentioned. Millions of individuals have been identified with illnesses caused by DNA, according to Lango, who said that DNA sequencing is “now making it feasible to produce remedies.”
- The second effect that G.C.T. might have, according to him, is on food. According to Lango, millions of Americans are sickened each year by food-borne diseases, and DNA sequencing is changing how we “avoid disease transmission in the food supply chain.”
- Finally, Lango discussed the potential influence of G.C.T. on manufacturing, using Nylon plastic as an example, which is created from petrochemicals and crude oil and is used in almost everything. Lango claims that these polymers may now be made without crude oil thanks to DNA synthesis and synthetic biology.
When it comes to DNA sequencing and synthetic biology, there are a plethora of additional possible applications in many industries, but these were the ones Lango discussed. And, although I always advise doing your own research, everything he described seemed to be accurate.
Apart from the technology itself, another important aspect of Luke Lango’s forecast is where we are in the development and adoption cycle of this technology.
In other words, “any breakthrough technology you can think of,” according to Lango, has two separate phases: the “Gradual Phase” and the “Sudden Phase.”
In the video, he describes the S-curve of innovation, in which new technology is initially pricey and adoption is restricted while it is being developed. However, if prices fall and the technology becomes more common in the second phase, adoption rates might skyrocket.
According to Luke Lango, “DNA sequencing is now in the Sudden Phase” because to a huge decrease in the cost of sequencing DNA.
“It used to cost more to sequence your DNA than the president’s Air Force One jet…
However, it may soon be as cheap as spare change.
Simply said, this is a once-in-a-lifetime price decrease.
And, as we’ve seen in the past with new technology…
They enter the Sudden Phase when they become affordable enough for the majority to embrace.”
Furthermore, he thinks one business is the “crown jewel” of this “tech revolution,” comparing it to Microsoft in the 1990s when internet use skyrocketed.
“There is one business, in particular, that I feel is the crown gem of this technological revolution.
It’s doing for G.C.T. what Microsoft did for the internet in the 1990s when it entered the Sudden Phase…”
Lango even speculates that it may be the “next Microsoft.”
“Because one little-known firm is at the epicenter of this new technological revolution.”
According to experts, this firm has the potential to be the next Microsoft.
And my firm’s analysts couldn’t agree more.”
What firm is he referring to?
The “#1 GCT Company” of Luke Lango (Stock Revealed)
As I previously said, the only way to learn more about Luke Lango’s “#1 GCT Company” is to sign up for his Innovation Investor service.
But after studying his hints, I think I’ve figured out which stock he’s taunting.
Here are some of Luke Lango’s key insights on the company:
“And my investigation has brought me to what may be the DNA era’s software behemoth.”
The firm is led by an MIT scientist who was a key contributor to the development of ARPANET, the technology that lay the groundwork for the internet.
He founded this fantastic firm in 2009 after seeing the immense potential in DNA and the lowering prices of sequencing.
It specializes in microbial DNA programming…
After then, such programs are licensed to corporations who employ them to create tangible materials, consumer goods, and other items.
That’s why According to experts, this firm has the potential to be the next Microsoft.
And here’s the best part: Bill Gates has already publicly endorsed and invested in this startup with his own money.”
As a result, we know Lango is after a DNA sequencing firm that specializes in programming DNA and licensing such “programs” to other businesses.
We also know that the firm was founded in 2009, that it is led by an MIT scientist who was involved in the development of ARPANET, and that Bill Gates has invested in it.
What further hints did he provide?
According to Luke Lango, Quest Diagnostics, Cronos Group, and Bayer are among the company’s “key relationships.”
What could it possibly be?
Lango’s “G.C.T.” stock selection, I assume, is Ginkgo Bioworks (ticker: DNA).
Lango’s presentation reminded me of a recent Whitney Tilson pitch I reported about, branded “America’s Next Big Monopoly,” in which he, too, teased Ginkgo Bioworks.
So, after seeing Lango’s presentation, the first thing I did was check to see whether Ginkgo Bioworks was a match since that was my guess, and it was.
Here’s a quick rundown of how it corresponds to Lango’s clues:
- Ginkgo Bioworks is a biotech business situated in Boston that was established in 2009. Although DNA sequencing is an important part of the business, the firm is also developing a platform that will allow clients to program cells as simply as they would a computer, according to the company’s website. It’s also concentrating on automating and scaling the organism engineering process. As a result, it seems to be consistent with Lango’s description.
- MIT scientists were among the company’s co-founders. One is CEO Jason Kelly, and the other is Tom Knight, who was a key figure in the development of ARPANET throughout the 1960s and 1970s.
- Ginkgo Bioworks received a $275 million investment from Bill Gates.
- Finally, all three of the firms named by Lango have partnered with the company.
Lango’s “#1 GCT company” is Ginkgo Bioworks.
In the presentation, he also mentioned a second firm, and after looking over his hints, I believe I know what that one is as well.
This second firm is related to the “gadget” (DNA sequencing machine) mentioned by Luke Lango at the start of the presentation (which I shared a screenshot of earlier).
Here are some of his hints:
“Do you recall seeing the DNA sequencer I showed you earlier?”
There’s a reason I picked THIS one as the subject of today’s lecture.
Because this technology is at the forefront of the most recent sequencing breakthrough.
A ‘Third Generation Sequencer’ is what it’s called.[…]
“This company’s invention is patented, therefore none of its rivals can copy it!”[…]
“It’s previously been used on the International Space Station to sequence DNA.”
That’s not much to go on, but after looking into which DNA sequencers have been used on the International Space Station, I found this article demonstrating that the MinION sequencing machine has been used to sequence DNA in space.
And I assume this is the “gadget” mentioned by Luke Lango during his presentation.
Why? The MinION sequencing equipment, which seems to be the device Lango mentioned in his presentation, has been utilized on the International Space Station, and the article classified it as a third-generation sequencer. To put it another way, it backs up what Lango stated.
But I was still looking for confirmation. So I went to the website of Oxford Nanopore Technologies, the company that develops the MinION, and the gadget featured on the MinION product page seems very identical to what Luke Lango described in his presentation.
So this is the sequencer he’s talking about.
Oxford Nanopore Technologies Limited is situated in the United Kingdom, although it trades on the OTC (over-the-counter) market under the ticker ONTTF.
So there you have it, two options for the cost of one (lol).
Of course, they are simply my educated estimates, and I make no guarantees that I am correct. And I don’t recommend anybody make any investing choices based on what I’ve said. I’m not sure whether any of the stocks I suggested are suitable buys.
But I believe this is what Lango is hinting towards. And the only way to find out for sure is to use his service, Innovation Investor. Because you receive access to the study papers he’s put together on each of his recommendations as a subscription.
In the following part, I’ll give you a summary of the service, what you receive if you sign up, and my thoughts on whether it’s a legitimate and valuable service.
Investor in Innovation: A Quick Overview
Luke Lango of InvestorPlace runs Innovation Investor, a stock advising service that focuses on “transformative technological investing prospects,” as he calls them.
Every month, he publishes a new edition of Innovation Investor, which contains his most recent research and investment recommendations. You may choose which investment ideas you want to follow and which ones you want to ignore as a subscriber.
Aside from the newsletters, you’ll get access to a model portfolio with Lango’s most recent active stock choices, a daily breakdown with Lango sharing his market thoughts and portfolio updates, and the following research reports.
- The Next Microsoft: The $80 Trillion DNA Revolution is Powered by a Software Company.
- The Next Big Thing in DNA Sequencing
- Three AI Stocks to Buy Right Now
The first two reports go over the firms he mentioned during his presentation (the ones I just mentioned), while the third one goes over three AI-related stocks. However, Lango didn’t provide much details on those stocks, so I’m not sure what they are.
Nonetheless, it is the essence of what you receive as an Innovation Investor membership. It’s basically a tech-focused investing research service in which Lango provides his best recommendations in fields such as electric cars, artificial intelligence, and DNA sequencing, among others.
If you join via the ordinary InvestorPlace sign-up page, it costs $199, but Lango is offering a deal as part of his “GCT” pitch that lets you to join for $79. Although there are more expensive ($99 or $129) alternatives that include extra study papers.
Check out my Innovation Investor review to learn more about the service. I go through how the service works and what’s included in it in more depth.
If you don’t want to bother reading that… In the end, if you’re interested in tech or biotech companies, the service is legitimate and maybe profitable. There’s no assurance you’ll make money; no business can guarantee that, but it is a legitimate service.
Luke Lango: Who Is He?
Luke Lango is a financial expert who works for InvestorPlace, a financial publishing firm that characterizes him as a “growth-focused stocks investor and analyst.”
Lango manages a number of services for InvestorPlace, including the Daily 10X Stock Report, Early Stage Investor, and the Crypto Investor Network, in addition to Innovation Investor. And, based on what I’ve observed, the majority of his selections are in the IT or biotech fields.
Before joining InvestorPlace, Lango was the founder of an investment fund (L&F Capital Management, LLC) and worked at a startup called Scoutables.
Is he someone with a strong track record?
I’m not familiar with Lango’s whole track record, but he seems to be one of the better stock pickers out there.
On TipRanks, an independent platform that analyzes various stock picker tips, he was recognized as the best financial blogger in 2020.
Lango has “named 14 different equities that have skyrocketed from 1,000 percent to as high as 12,000 percent in value” during the last four years, according to the presentation. In the presentation, he gave several instances of his successful choices.
However, there are two key limitations to this.
To begin with, just because someone has consistently chosen excellent stocks in the past does not guarantee that they will continue to do so in the future. As a result, you shouldn’t anticipate his suggestions to earn you money. Second, Lango has undoubtedly made his fair share of bad bets.
In any case, based on what I’ve seen, he’s the genuine deal. I’ve written about other of his presentations if you want to see what other stocks he recommends.
For instance, I just wrote about a LiDAR firm that he mocked. Before that, I discovered his stock recommendation for “eternal batteries.”
So you may want to have a look at them since I break down his decision in a similar fashion to what I’ve done here in each of the prior blogs.
The “G.C.T.” talk by Luke Lango focuses on DNA sequencing and the potential advantages of this technology in industries such as healthcare, manufacturing, and agriculture.
He also hinted at two firms he’s interested in throughout the presentation.
Ginkgo Bioworks, according to my study, is the #1 firm, while Oxford Nanopore Technologies Limited is the second.
However, as previously said, the only way to be certain is to subscribe to Innovation Investor, his tech and biotech-focused advice for InvestorPlace.
It’s up to you whether or not you join; I’m not linked with this firm, therefore it doesn’t matter to me. But, in any case, I hope you find what I’ve provided useful. And, if you have any ideas on any of this, please do so in the comments section below. Thank you for taking the time to read this.
- gene sequencing
- dna sequencing
- genome sequencing